New oral drug trial aims to slow scarring in fatal lung disease
Disease control
Recruiting now
This study is testing whether an oral medication called PIPE-791 can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 324 adults with IPF will take either PIPE-791 or a placebo pill for 26 weeks to see if th…
Phase: PHASE2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC